ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

Sole Source Negotiations

March 7, 1975

NIH grant success rate drops to under 20 percent after 2011 budget cuts

May 13, 2011

A Take-Home Message From ASCO 2014: NCI-Funded Clinical Research In Jeopardy,bSociety Focuses on Value of NCTN Groups

June 6, 2014

New Health Bills Could Affect Cancer Program

February 9, 1979

Sister Study To Examine Risk Factors For Breast Cancer In 50,000 Women

October 29, 2004

Neutron Therapy Contracts Wind Down Next Year; DCT To Consider Whether To Continue Support

March 25, 1988